Literature DB >> 7237794

Labile glycosylated hemoglobin contributes to hemoglobin A1 as measured by liquid chromatography or electrophoresis.

D M Nathan.   

Abstract

The utility of glycosylated hemoglobin (HbA1) measurement as an index of chronic control in diabetes can be adversely affected by interference from a labile glycosylated fraction that changes rapidly with acute changes in blood glucose concentration. I used a "high-pressure" liquid-chromatographic assay and a newly developed electrophoretic assay to quantitate the contribution of this labile fraction. If erythrocytes are incubated at 22 degrees C in isotonic saline for 12 h before hemolysis, the labile fraction is eliminated. Its contribution is similar as measured by both assays: 2-3.5% of total HbA1 in normal cells and 7-9.5% in diabetic cells. A 3-h incubation of erythrocytes with glucose produces acute changes in apparent HbA1 concentrations by both assays, but such changes can be eliminated by the incubation in saline. Although current methods are time consuming, the labile glycosylated hemoglobin must be removed when the sample is prepared for HbA1 measurement by liquid chromatography and electrophoresis if results are not to be factitiously high.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7237794

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

1.  HbA1 in assessment of metabolic control in diabetic BB/E rats.

Authors:  F J Tames; J D Baird; A J Bone
Journal:  Diabetologia       Date:  1990-05       Impact factor: 10.122

2.  Glycosylated haemoglobin and plasma glycoprotein assays by affinity chromatography.

Authors:  D G Willey; M A Rosenthal; S Caldwell
Journal:  Diabetologia       Date:  1984-07       Impact factor: 10.122

3.  Changes in glycemic control from 1996 to 2006 among adults with type 2 diabetes: a longitudinal cohort study.

Authors:  Karen J Blumenthal; Mary E Larkin; Gail Winning; David M Nathan; Richard W Grant
Journal:  BMC Health Serv Res       Date:  2010-06-09       Impact factor: 2.655

4.  Serum fructosamine and glycated haemoglobin measurements in diabetic control.

Authors:  E J Hindle; G M Rostron; S A Clark; J A Gatt
Journal:  Arch Dis Child       Date:  1986-02       Impact factor: 3.791

5.  Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%.

Authors:  Lydie Nkwimi Pani; David Matthew Nathan; Richard William Grant
Journal:  Diabetes Care       Date:  2007-12-14       Impact factor: 19.112

6.  Predictive value of serum adiponectin and hemoglobin levels for vascular cognitive impairment in ischemic stroke patients.

Authors:  Zhouling Li; Manlian Zhu; Cheng Meng; Hai Lin; Lifen Huang
Journal:  Pak J Med Sci       Date:  2022 Mar-Apr       Impact factor: 1.088

7.  Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study.

Authors:  Marie-France Hivert; Alisa K Manning; Jarred B McAteer; Josée Dupuis; Caroline S Fox; L Adrienne Cupples; James B Meigs; Jose C Florez
Journal:  Diabetes       Date:  2008-12-15       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.